Cargando…

Chronic hepatitis B: New potential therapeutic drugs target

Chronic hepatitis B (CHB) infection remains the most causative agent of liver-related morbidity and mortality worldwide. It impacts nearly 300 million people. The current treatment for chronic infection with the hepatitis B virus (HBV) is complex and lacks a durable treatment response, especially he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leowattana, Wattana, Leowattana, Tawithep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788212/ https://www.ncbi.nlm.nih.gov/pubmed/35117971 http://dx.doi.org/10.5501/wjv.v11.i1.57

Ejemplares similares

COVID-19 vaccination and cardiac dysfunction
por: Leowattana, Wattana, et al.
Publicado: (2022)

Potassium-competitive acid blockers and gastroesophageal reflux disease
por: Leowattana, Wattana, et al.
Publicado: (2022)

Dengue hemorrhagic fever and the liver
por: Leowattana, Wattana, et al.
Publicado: (2021)

Human-induced pluripotent stem cell-atrial-specific cardiomyocytes and atrial fibrillation
por: Leowattana, Wattana, et al.
Publicado: (2022)

Circulating angiotensin converting enzyme 2 and COVID-19
por: Leowattana, Wattana, et al.
Publicado: (2022)

Systemic treatment for metastatic colorectal cancer
por: Leowattana, Wattana, et al.
Publicado: (2023)

Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer
por: Leowattana, Wattana, et al.
Publicado: (2023)

Systemic treatments for resectable carcinoma of the esophagus
por: Leowattana, Wattana, et al.
Publicado: (2023)

Immunotherapy for advanced gastric cancer
por: Leowattana, Wattana, et al.
Publicado: (2023)

Systemic treatment for unresectable hepatocellular carcinoma
por: Leowattana, Wattana, et al.
Publicado: (2023)

Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in coronavirus disease 2019 patients
por: Leowattana, Wattana
Publicado: (2021)

Tuberculosis of the spine
por: Leowattana, Wattana, et al.
Publicado: (2023)

Systemic treatment for advanced pancreatic cancer
por: Leowattana, Wattana, et al.
Publicado: (2023)

Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B
por: Aung, Myo Nyein, et al.
Publicado: (2010)

Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand
por: Thu, Aung Myint, et al.
Publicado: (2015)

Hepatitis delta virus: From infection to new therapeutic strategies
por: Niro, Grazia A, et al.
Publicado: (2021)

Increased fluidity and oxidation of malarial lipoproteins: relation with severity and induction of endothelial expression of adhesion molecules
por: Sibmooh, Nathawut, et al.
Publicado: (2004)

Risk perception of health problems among travelers visiting a travel clinic in Bangkok, Thailand
por: Hiranrusme, Thanyapat, et al.
Publicado: (2020)

Discontinuation of antiviral therapy in chronic hepatitis B patients
por: Medas, Renato, et al.
Publicado: (2021)

Challenges in the discontinuation of chronic hepatitis B antiviral agents
por: Kaewdech, Apichat, et al.
Publicado: (2021)

Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases
por: Kawanaka, Miwa, et al.
Publicado: (2021)

Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis
por: Wu, Ya-Li, et al.
Publicado: (2019)

Chronic hepatitis B in pregnant women: Current trends and approaches
por: Belopolskaya, Maria, et al.
Publicado: (2021)

ARF-BP1 as a potential therapeutic target
por: Chen, D, et al.
Publicado: (2006)

TMPRSS4: an emerging potential therapeutic target in cancer
por: de Aberasturi, A L, et al.
Publicado: (2015)

The complexity of integrins in cancer and new scopes for therapeutic targeting
por: Hamidi, Hellyeh, et al.
Publicado: (2016)

Klotho: A new therapeutic target in diabetic retinopathy?
por: Puddu, Alessandra, et al.
Publicado: (2023)

Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients
por: Lee, Hye Won, et al.
Publicado: (2016)

Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients
por: Guo, Jiang, et al.
Publicado: (2021)

The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer
por: Sheng, Q, et al.
Publicado: (2011)

RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets
por: Chen, Shao-Long, et al.
Publicado: (2021)

Gut microbiome therapeutic modulation to alleviate drug-induced hepatic damage in COVID-19 patients
por: Ahsan, Khansa, et al.
Publicado: (2023)

Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure
por: Shinn, Brianna J, et al.
Publicado: (2019)

Stem cells, quiescence and rectal carcinoma: an unexplored relationship and potential therapeutic target
por: Buczacki, S, et al.
Publicado: (2011)

Apelin-APJ Signaling: a Potential Therapeutic Target for Pulmonary Arterial Hypertension
por: Kim, Jongmin
Publicado: (2014)

Protease-activated receptor 1 as a potential therapeutic target for COVID-19
por: Rovai, Emanuel S., et al.
Publicado: (2020)

Mimicking platelet indices in patients with malaria and dengue hemorrhagic fever: characteristics and clinical applications
por: Mon, Nant The Su, et al.
Publicado: (2022)

Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA
por: Sekiba, Kazuma, et al.
Publicado: (2018)

Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease
por: Khoo, Tiffany, et al.
Publicado: (2021)

Golgi Stress Response: New Insights into the Pathogenesis and Therapeutic Targets of Human Diseases
por: Kim, Won Kyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ntep2e5k9bl5u4gl9m0df4j89u